about
Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodiesThe crystal structure of IgE Fc reveals an asymmetrically bent conformationThe crystal structure of rabbit IgG-FcConformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcɛRI.Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor Fc RICa2+-dependent Structural Changes in the B-cell Receptor CD23 Increase Its Affinity for Human Immunoglobulin EConformational plasticity at the IgE-binding site of the B-cell receptor CD23A range of C∊3–C∊4 interdomain angles in IgE Fc accommodate binding to its receptor CD23Human immunoglobulin E flexes between acutely bent and extended conformations.Activated ezrin promotes cell migration through recruitment of the GEF Dbl to lipid rafts and preferential downstream activation of Cdc42IgE binds asymmetrically to its B cell receptor CD23Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab.The biology of IGE and the basis of allergic disease.Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.Soluble CD23 controls IgE synthesis and homeostasis in human B cells.Inhibition of allergen-dependent IgE activity by antibodies of the same specificity but different class.Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application.Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling.Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity.Analysis of the interaction between RGD-expressing adenovirus type 5 fiber knob domains and alphavbeta3 integrin reveals distinct binding profiles and intracellular trafficking.IgE Trimers Drive SPE-7 Cytokinergic Activity.Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.Attenuation of IgE affinity for FcepsilonRI radically reduces the allergic response in vitro and in vivoThermal sensitivity and flexibility of the Cε3 domains in immunoglobulin E.Total synthesis of (+/-)-aspercyclide A and its C19 methyl ether.A small-molecule activator of kinesin-1 drives remodeling of the microtubule network.Synthesis and incorporation into cyclic peptides of tolan amino acids and their hydrogenated congeners: construction of an array of A-B-loop mimetics of the Cε3 domain of human IgE.Allergen specificity of IgG4-expressing B cells in patients with grass pollen allergy undergoing immunotherapyHeterogeneous Glycosylation of Immunoglobulin E Constructs Characterized by Top-Down High-Resolution 2-D Mass Spectrometry†Structure based design and characterization of peptides that inhibit IgE binding to its high-affinity receptorSynthesis of the C19 methyl ether of aspercyclide A via germyl-Stille macrocyclisation and ELISA evaluation of both enantiomers following optical resolutionBent Domain Structure of Recombinant Human IgE-Fc in Solution by X-ray and Neutron Scattering in Conjunction with an Automated Curve Fitting ProcedureStructure of a patient-derived antibody in complex with allergen reveals simultaneous conventional and superantigen-like recognitionStructural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibody
P50
Q27345217-15C6AEEF-E63C-4A97-AD6D-06977ADDEFFAQ27639182-E4725F10-377C-4C54-AA88-771F710EFF3AQ27651917-76E9F658-9E4D-42B4-A0DB-C7A6973FD499Q27667551-9B29DF43-E886-4D0C-8874-031C05FAC2A4Q27670759-C2F2FF50-54DE-4EA6-AAD2-5700FD33B3DFQ27678651-57E330FD-3971-4BB8-B395-C93F0D65F5E5Q27679499-23E23955-C4A3-462B-9BD3-8A5B5E48E706Q27682020-BA04E520-3351-4C0E-A605-BDE3B550894FQ27682236-4C859A41-9BED-49A2-A172-F2BCFFC62C8BQ30479901-F444FC6D-CF97-4DEC-B22B-AB7D133E2188Q30843434-66621F37-B352-405A-A779-2E2E2C895A6AQ30855879-25FA1E09-5F54-4AFB-97D3-4A540F363711Q34167019-864D3EE4-3E10-429C-87AE-EB410BCFB498Q34475414-89B16487-EF3E-4E94-BF31-BA6539806280Q36043674-B74B8709-1C85-4FD6-8AA2-4551408D3A5AQ37105631-1AB20005-840D-4384-B392-E94814386FBFQ37964490-80A8C4E3-B1AE-4BDF-8F40-9D19C9EF2ADCQ38720904-340EFD18-4F7F-4E6A-8DF4-1BFFE6C30C9AQ39543380-CF851C6B-5BEA-499B-9DC6-229C7AFB2178Q40246202-7F1F352B-7A62-4D3C-BA99-C8819F9A200CQ41421207-36E83C3D-AC36-458C-9EB7-5EA132BF3E8BQ41673094-3172114B-ADA4-447C-A2CE-82E7369925C5Q41897470-534DB0D2-CAA9-410D-832A-66AE2A6464E8Q42650125-04348EEF-2934-4DEE-AEA6-F37D6984FC1DQ43144528-3CAC69F8-6002-4325-87CF-7C89CB7BCA8BQ48138968-A287FA63-11CA-4D2B-986A-8585A3A91F80Q52622734-BD6230CF-407E-417E-A070-1495CFB22550Q58428742-318BE251-1518-417E-90BF-29118D02F684Q58428803-7B236254-1AA7-4879-936B-0014877A8D77Q58428845-815AA824-D637-41CD-B578-CC6A7F99F98FQ58429016-03C4CC42-3368-4CE6-8789-9F1DC6E5B287Q58429063-A1B21198-7148-4052-A692-EAD747D40F3EQ58700268-4A863534-0E61-4F9A-AB40-F017C3A70514Q60628285-9C71A432-0955-4E37-A020-A80363285B34
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Andrew J. Beavil
@ast
Andrew J. Beavil
@en
Andrew J. Beavil
@es
type
label
Andrew J. Beavil
@ast
Andrew J. Beavil
@en
Andrew J. Beavil
@es
prefLabel
Andrew J. Beavil
@ast
Andrew J. Beavil
@en
Andrew J. Beavil
@es
P106
P1153
6603327993
P21
P31
P496
0000-0002-0768-122X